发布时间: 2026 - 04 - 27
Highlands Pharmaceuticals today announced positive topline results from its Phase III clinical trial ("TARA Study") evaluating Ginositinib, an oral small-molecule JAK1/TYK2 inhibitor, for the treatment of active rheumatoid arthritis (RA). The study met its primary and all secondary efficacy endpoints, demonstrating statistically superior outcomes compared to the positive control drug Tofacitinib (Xeljanz), along with a favorable safety and tolerability profile. This marks the first registrational study globally to use another JAK inhibitor as a positive control and achieve superior e...
浏览次数:2
发布时间: 2026 - 04 - 24
Today, at the highly anticipated "ChinaVenture 20th Annual Investment Summit · Annual Conference," the prestigious ChinaVenture Awards list was officially unveiled. Leveraging its deep expertise in the healthcare industry, EFUNG Capital swept multiple significant institutional and individual awards.EFUNG Capital was honored with: ChinaVenture 2025 Top 50 Best RMB-denominated Venture Capital Firms, ChinaVenture 2025 Top 20 Medical Device Investment Institutions in the Healthcare Sector, and ChinaVenture 2025 Top 100 Best Venture Capital Firms.At the same time, Mr. Zhu Pai, CEO of...
浏览次数:2
发布时间: 2026 - 04 - 02
Editor's NoteLast month, a doctor friend shared his confusion with me.A patient had just sat down when he thrust his phone in front of the doctor. The screen was densely packed with AI-generated "treatment recommendations"—from medication plans to lifestyle restrictions, covering every detail. With a hint of scrutiny, the patient asked: "Doctor, the AI says this medication has serious side effects. Your prescription is different. Could you double-check?"My friend was stunned. He had encountered patients who came with Baidu search results to "argue their case,"...
浏览次数:3
发布时间: 2026 - 03 - 24
In March, Suzhou is gradually embracing the vitality of spring, much like China's biomedical industry, which is gathering momentum amidst transformation. On March 13, during the 11th BioChina Summit (BIOCHINA 2026), Mr. Zhu Pai, CEO of Efung Capital, was invited to attend the core session—the Global Investment Forum—where he engaged in in-depth discussions with industry peers on the theme "LP-GP Ecosystem Synergy: Coordinating Policy, Capital, and Innovation."Efung Capital CEO Zhu Pai Attends BIOCHINA 2026: Discussing the New Ecosystem of LP-GP Collaboration, Standing as "Ba...
浏览次数:8
71页次2/18首页PREV12345678910...NEXTlast page
Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务